Treatment and prevention of tissue damage
AssigneePentraxin Therapeutics Limited
InventorMark B. Pepys
Life of this patent
Estimating the term…
Abstract
A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.
Claims48
A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand thereof.
A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound of general formula (I):
- 2
- wherein X is H or an organic substituent group, and Y is N substituted to form ammonium.
A method for the treatment or prevention of tissue damage in a subject having an inflammatory/tissue damaging condition, which comprises administering to the subject an effective amount of a compound comprising hexadecylphosphocholine.
A method for the treatment or prevention of atherosclerosis in a subject which comprises administering to the subject an effective amount of a compound capable of inhibiting binding of C-reactive protein (CRP) to an autologous or extrinsic ligand thereof.
A method for the treatment or prevention of tissue damage in a subject having a myocardial infarction, which comprises administering to the subject an effective amount of a compound capable of inhibiting binding of C-reactive protein (CRP) to its autologous or extrinsic ligand thereof at or after the onset of the infarction.
A method for the treatment or prevention of a thrombotic complication of atherosclerosis in a subject which comprises administering to the subject an effective amount of a compound capable of inhibiting binding of C-reactive protein (CRP) to an autologous or extrinsic ligand thereof.
A method for the treatment or prevention of tissue damage in a subject with myocardial infarction, which comprises administering to the subject an effective amount of a compound comprising hexadecylphosphocholine.
A method for selecting a pharmaceutical compound for treating or preventing tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises contacting C-reactive protein (CRP) with a ligand thereof under conditions to permit CRP ligand binding, in the presence of a test compound;
- and selecting the test compound as the pharmaceutical compound if the test compound inhibits binding of CRP to the ligand
Dependencies are inferred from the claim text.